Haemonetics (NYSE: HAE) reported Q1 EPS of $1.10, $0.09 better than the analyst estimate of $1.01. Revenue for the quarter came in at $321.39 million versus the consensus estimate of $302.62 million.

For earnings history and earnings-related data on Haemonetics (HAE) click here.